![Teva Announces Ministry of Health, Labour and Welfare Approves AJOVY® (fremanezumab) Injection in Japan for the Preventive Treatment of Migraine in Adults | Business Wire Teva Announces Ministry of Health, Labour and Welfare Approves AJOVY® (fremanezumab) Injection in Japan for the Preventive Treatment of Migraine in Adults | Business Wire](https://mms.businesswire.com/media/20210623005566/en/739014/23/teva_RGB_JPEG.jpg)
Teva Announces Ministry of Health, Labour and Welfare Approves AJOVY® (fremanezumab) Injection in Japan for the Preventive Treatment of Migraine in Adults | Business Wire
![PDF) CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs PDF) CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs](https://i1.rgstatic.net/publication/355584267_CGRP_monoclonal_antibodies_in_migraine_an_efficacy_and_tolerability_comparison_with_standard_prophylactic_drugs/links/61778e693c987366c3e9bbe3/largepreview.png)
PDF) CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
![Teva Canada Announces New Autoinjector for AJOVY® for the Preventive Treatment of Migraine in Adults | Business Wire Teva Canada Announces New Autoinjector for AJOVY® for the Preventive Treatment of Migraine in Adults | Business Wire](https://mms.businesswire.com/media/20210408005437/en/713670/5/teva_RGB_JPEG.jpg)